Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Financial Performance and Strategy news
(page 6)
22 April 2026
Croda Q1 2026 sales meet guidance
Q1 sales £431m, +1% CC; Beauty Actives and F&F offset weaker Crop Protection. Transformation on track; FY26 outlook unchanged. Latin America strongest; North America weaker.
22 April 2026
Evonik expands biotech drug-substance capacity in Slovakia
€80M expansion adds downstream fermentation for drug‑substance manufacturing, creates ~50 jobs; follows rhamnolipids plant and boosts biotech scale‑up and sustainability.
21 April 2026
INEOS Inovyn to sell Italian chlor-alkali business to Esseco Industrial
Sale covers Rosignano and Tavazzano chlor‑alkali plants; regulatory approval required, expected 2026. Seller manages sites until closing; customer/supplier terms unchanged. Rosignano R&D retained.
21 April 2026
Evonik opens expanded specialty-amine plant in Nanjing
Double-digit-million-euro expansion boosts specialty amine capacity in Nanjing, improving supply security, raw-material access and low-VOC additives for polyurethane/epoxy; plant runs on green power
21 April 2026
OCI Global sells remaining Methanex stake
Sold 2,612,962 shares (~3.4%) in a block trade at US$52.85 each on 20 April; net proceeds ≈US$138.1M. May acquire or dispose of such securities in the future.
20 April 2026
Elkem sells Saguenay biocarbon unit to CHAR Tech, secures 5‑year 62,500‑t supply
Sale transfers pilot/demo facility and proprietary pellet tech; site to be upgraded to 15,000 t/yr of pellets, converting raw biochar into biocarbon for ferrosilicon decarbonisation and smelter supply.
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
20 April 2026
Boehringer Ingelheim launches £150M AI accelerator in London’s Knowledge Quarter
Adds a new Computational Innovation centre to the global footprint, focusing on AI/ML for drug R&D to deepen disease biology and speed discovery; first 50 AI experts by end of 2027.
20 April 2026
Lilly to acquire Kelonia Therapeutics for in vivo CAR‑T platform
Buyer will acquire a clinical-stage in vivo CAR-T developer for up to $7B (incl. $3.25B upfront). Lead KLN-1010 (lentiviral anti-BCMA) showed promising Phase 1 ASH data; close expected H2 2026.
20 April 2026
MAIRE raises €185m sustainability‑linked Schuldschein to refinance facilities
€185M sustainability‑linked Schuldschein, 3‑ and 5‑yr (margins 1.50%/1.70% over 6M Euribor). For early refinancing; upsize option to €300M. Linked to 2028 decarbonization targets.
20 April 2026
Asahi Kasei Acquires Aicuris to Expand Infectious-Disease Pharma Portfolio
Acquisition adds three antiviral assets - royalties from Prevymis, pritelivir (FDA Priority Review; PDUFA Q4 2026) and AIC468 - aims $500M revenue by 2030 and transplant/infectious-disease growth.
20 April 2026
Eni’s Geliga‑1 Giant Gas Discovery in Indonesia’s Kutei Basin — ≈5 Tcf gas, 300 MMbbl condensate
Geliga‑1 hit a high‑quality Miocene gas column; DST planned. Discovery bolsters basin scale, may enable a fast‑track third production hub by tying into nearby Gula and existing infrastructure
17 April 2026
AkzoNobel to sell Pakistan business to Packages Group
Deal values unit at PKR 16.2bn (~€50m) at 14x EV/EBITDA. Includes Decorative Paints; Future Coatings will pay royalties. Closing expected H2 2026, subject to conditions.
16 April 2026
EIB, EC and IFC back Biovac to build Africa’s first end-to-end vaccine manufacturing plant
€75M quasi‑equity and $20M senior loan finance a South African end‑to‑end multi‑vaccine plant (2028) to produce cholera, polio, pneumonia and meningitis vaccines (30–40M doses/yr); 340 skilled, 7,000 indirect jobs.
16 April 2026
Petrobras: Ordinary General Meeting decisions
Approved 2025 accounts and 2026 capital budget; allocated 2025 results with two equal payments (May 20, Jun 22); elected 11 directors and 5 fiscal council members; set remuneration caps.
16 April 2026
BioLamina secures €20m EIB financing to scale laminin-based cell therapies
Venture-debt financing backed by InvestEU will scale production of cell-culture substrates, expand tech and product range, enable animal-free drug testing and support therapies for chronic diseases.
15 April 2026
Stegra secures €1.4bn to complete Boden green steel plant
Wallenberg-led consortium agreed financing to finish the plant (>60% complete). Funding covers scope increases, cost rises and buffer; it will cut CO2 ~95% using green hydrogen.
15 April 2026
PPG acquires pavement-marking maker Ozark Materials
All-cash $65M purchase of a U.S. pavement-marking supplier serving US and Canada. About 130 employees; strengthens Traffic Solutions and North American market presence.
15 April 2026
EIB lends €100m to Orion Pharma for oncology and pain R&D
Financing will support clinical trials, staff, patents and lab equipment, boosting clinical development capacity, supply security for critical medicines and EU biopharma competitiveness.
15 April 2026
GSK acquires 35Pharma for $950m
Deal closed for biotech developing HS235, an activin‑receptor therapy for pulmonary hypertension; designed to cut bleeding risk and offer metabolic benefits. PoC trials in PAH and PH‑HFpEF planned.
14 April 2026
Petrobras to invest $450M in world's largest seabed seismic monitoring project
Permanent seabed seismic sensor network in Mero (Santos Basin) will map reservoir behavior to improve recovery and monitor FPSO production. 460 km cables in place; first data Q2 2026; AI used.
14 April 2026
Iberdrola adds 42 MW Lazio PV, bringing Italy capacity to ~400 MW
Plant (commissioned <6 months) backed by long‑term PPAs joins Etruria and Fenix projects; deal pending closing and aligns with group's €58bn 2025–28 investment plan.
14 April 2026
Equinor sells 8.07% stake in Scatec, retains 8.05%
Sold at NOK125/share for ~NOK1.6bn; remaining holding subject to 90‑day lock‑up. Average in‑price ~NOK80/share; Brazilian solar partnerships unaffected.
14 April 2026
Genmab: DARZALEX Q1 2026 net sales USD 3,964m
DARZALEX Q1 sales split: US $2,208m; RoW $1,756m. Includes subcutaneous FASPRO in U.S. Royalties received under J&J exclusive license.
14 April 2026
OCI Global sells 2M Methanex shares for ~$116.6M
Block trade on 13 April; ownership fell from ~6.0% to ~3.4%. Transaction was for investment purposes; company may repurchase or further sell shares depending on market and the stock's performance.
13 April 2026
Petrobras greenlights SEAP I FID and advances contracting of two Sergipe‑Alagoas platforms
SEAP II FID had been approved earlier. SBM Offshore to build two BOT FPSOs with combined 240,000 bbl/d and 22 MMm3/d gas. Contract signing May 2026; production ~2030/2031; investment >R$60bn.
13 April 2026
Petrobras approves restart of UFN III fertilizer plant construction in Três Lagoas
Board approved resumption of UFN III construction; ~$1B to complete, operations in 2029; ~8,000 construction jobs; capacity ~3,600 t/d urea and 2,200 t/d ammonia; strategic for domestic supply
10 April 2026
Plenitude acquires Acea Energia
100% of an energy retail arm and 50% of a regional supplier acquired; adds 1.2M customers. Vulnerable customers excluded. Price ~€500M plus up to €100M earn‑out to 30/06/2027.
10 April 2026
Eni invests US$70M in Nouveau Monde Graphite
US$70M in a US$297M raise to fund Matawinie & Becancour; investor gains ~11.5% stake and board seat, secures exclusive graphite/anode supply for Brindisi gigafactory; pending AGM approval
10 April 2026
Petrobras to regain 100% of Tartaruga Verde and Espadarte Module III
Signed to acquire remaining 50% of Tartaruga Verde and Espadarte III for US$450M: $50M signing; $350M at close; two deferred $25M. Pending ANP approval. Fields producing ~55k b/d
9 April 2026
Boliden: SEK 700m write-down at Garpenberg mine
March seismic activity damaged the upper Lappberget ore body and infrastructure (ventilation, compressed air, water, power, backfill) and some mobile equipment. Production halt cuts Q1 EBITDA ~SEK 400m
← Previous
Next →
